Concepedia

Douglas Wilson

DW

Statistics

Publications

8

Citations

722

H-Index

8

Active since

2005

Affiliations

Blueprint Medicines (United States)(Current)

Yonsei University

Douglas Wilson is an author at Blueprint Medicines (United States) specializing in pharmacology, medicine, and tyrosine kinase inhibitors.

ORCID

Publications per year

2005–2024

8

Publications

8

Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers

Vivek Subbiah, Justin F. Gainor, Rami Rahal et al. · Cancer Discovery · 2018 · 393 citations

, , +17

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

Meredith S. Eno, Jason D. Brubaker, John E. Campbell et al. · Journal of Medicinal Chemistry · 2022 · 160 citations · Full text

, , +14

A Highly Facile and Efficient One-Step Synthesis of <i>N</i><sup>6</sup>-Adenosine and <i>N</i><sup>6</sup>-2‘-Deoxyadenosine Derivatives

Zhao‐Kui Wan, Eva Binnun, Douglas Wilson et al. · Organic Letters · 2005 · 63 citations

, , +9

1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC

Stefanie S. Schalm, Tom Dineen, Sangbin Lim et al. · Annals of Oncology · 2020 · 50 citations · Full text

, , +11

An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva

Alison Davis, Natasja Brooijmans, Jason D. Brubaker et al. · Science Translational Medicine · 2024 · 20 citations

, , +17

1–5 of 8